Published in Arthritis Rheum on February 01, 1995
IL-32, a proinflammatory cytokine in rheumatoid arthritis. Proc Natl Acad Sci U S A (2006) 2.67
Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann Rheum Dis (2000) 2.59
IL-17 derived from juxta-articular bone and synovium contributes to joint degradation in rheumatoid arthritis. Arthritis Res (2001) 2.12
Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. Int Immunol (2003) 2.02
Interleukin 1 receptor dependence of serum transferred arthritis can be circumvented by toll-like receptor 4 signaling. J Exp Med (2003) 1.99
CD8 positive T cells influence antigen-specific immune responses through the expression of chemokines. J Clin Invest (1998) 1.87
IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion. J Clin Invest (2000) 1.74
Th17 cytokines and arthritis. Semin Immunopathol (2010) 1.57
Suppression of experimental arthritis by gene transfer of interleukin 1 receptor antagonist cDNA. Proc Natl Acad Sci U S A (1996) 1.56
Biological basis for the use of botanicals in osteoarthritis and rheumatoid arthritis: a review. Evid Based Complement Alternat Med (2005) 1.55
Direct adenovirus-mediated gene transfer of interleukin 1 and tumor necrosis factor alpha soluble receptors to rabbit knees with experimental arthritis has local and distal anti-arthritic effects. Proc Natl Acad Sci U S A (1998) 1.54
In vivo transfer of interleukin-1 receptor antagonist gene in osteoarthritic rabbit knee joints: prevention of osteoarthritis progression. Am J Pathol (1999) 1.52
Fibrin(ogen) exacerbates inflammatory joint disease through a mechanism linked to the integrin alphaMbeta2 binding motif. J Clin Invest (2007) 1.52
Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis. Arthritis Res (1999) 1.51
Regulation of catabolic gene expression in normal and degenerate human intervertebral disc cells: implications for the pathogenesis of intervertebral disc degeneration. Arthritis Res Ther (2009) 1.46
Clinical and laboratory manifestations of elderly onset psoriatic arthritis: a comparison with younger onset disease. Ann Rheum Dis (1999) 1.45
Severe inflammatory arthritis and lymphadenopathy in the absence of TNF. J Clin Invest (2001) 1.40
Role of tumour necrosis factor alpha in experimental arthritis: separate activity of interleukin 1beta in chronicity and cartilage destruction. Ann Rheum Dis (1999) 1.37
Mast cells, cytokines, and metalloproteinases at the rheumatoid lesion: dual immunolocalisation studies. Ann Rheum Dis (1995) 1.35
Antibody-induced arthritis: disease mechanisms and genes involved at the effector phase of arthritis. Arthritis Res Ther (2006) 1.32
The dual role of interferon-gamma in experimental Staphylococcus aureus septicaemia versus arthritis. Immunology (1998) 1.30
Long-term follow-up of the changes in circulating cytokines, soluble cytokine receptors, and white blood cell subset counts in patients with rheumatoid arthritis (RA) after monoclonal anti-TNF alpha antibody therapy. J Clin Immunol (1999) 1.28
Activation of interleukin-1 signaling cascades in normal and osteoarthritic articular cartilage. Am J Pathol (2007) 1.28
Consumption of hydrolyzable tannins-rich pomegranate extract suppresses inflammation and joint damage in rheumatoid arthritis. Nutrition (2008) 1.25
Breast-cancer-associated metastasis is significantly increased in a model of autoimmune arthritis. Breast Cancer Res (2009) 1.25
Peptide-based Biopolymers in Biomedicine and Biotechnology. Mater Sci Eng R Rep (2008) 1.25
Constitutive transcription of the human interleukin-6 gene by rheumatoid synoviocytes: spontaneous activation of NF-kappaB and CBF1. Am J Pathol (1998) 1.24
The role of gp130-mediated signals in osteoclast development: regulation of interleukin 11 production by osteoblasts and distribution of its receptor in bone marrow cultures. J Exp Med (1996) 1.24
Early response genes induced in chondrocytes stimulated with the inflammatory cytokine interleukin-1beta. Arthritis Res (2001) 1.22
Rodent preclinical models for developing novel antiarthritic molecules: comparative biology and preferred methods for evaluating efficacy. J Biomed Biotechnol (2010) 1.16
Role of interleukin 1 and interleukin 1 receptor antagonist in the mediation of rheumatoid arthritis. Ann Rheum Dis (2000) 1.10
A new arthritis therapy with oxidative burst inducers. PLoS Med (2006) 1.09
Interleukin-10 modulates proinflammatory cytokines in the human monocytic cell line THP-1 stimulated with Borrelia burgdorferi lipoproteins. Infect Immun (2000) 1.09
Cartilage destruction by matrix degradation products. Mod Rheumatol (2006) 1.08
Intra-articular IL-10 gene transfer regulates the expression of collagen-induced arthritis (CIA) in the knee and ipsilateral paw. Clin Exp Immunol (2000) 1.07
The stressed synovium. Arthritis Res (2001) 1.07
Measurement of the serum leptin level could assist disease activity monitoring in rheumatoid arthritis. Rheumatol Int (2006) 1.06
Mast cell activation and its relation to proinflammatory cytokine production in the rheumatoid lesion. Arthritis Res (2000) 1.06
Interleukin-18 promotes joint inflammation and induces interleukin-1-driven cartilage destruction. Am J Pathol (2004) 1.06
Osteoarthritis: can anti-cytokine therapy play a role in treatment? Clin Rheumatol (2010) 1.02
Etanercept reduces the serum levels of interleukin-23 and macrophage inflammatory protein-3 alpha in patients with rheumatoid arthritis. Rheumatol Int (2007) 1.02
Role of tumor necrosis factor alpha, interleukin-1beta, and interleukin-6 in a mouse model of group B streptococcal arthritis. Infect Immun (1999) 1.02
RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison with anti-TNFalpha or anti-IL-1 therapies. Arthritis Res Ther (2009) 1.02
Cytokine expression and synovial pathology in the initiation and spontaneous resolution phases of adjuvant arthritis: interleukin-17 expression is upregulated in early disease. Clin Exp Immunol (2001) 1.02
PEGylated recombinant human soluble tumour necrosis factor receptor type I (r-Hu-sTNF-RI): novel high affinity TNF receptor designed for chronic inflammatory diseases. Ann Rheum Dis (1999) 1.01
Pregnancy in patients with rheumatic disease: anti-inflammatory cytokines increase in pregnancy and decrease post partum. Ann Rheum Dis (2004) 1.00
Effects of bucillamine and N-acetyl-L-cysteine on cytokine production and collagen-induced arthritis (CIA). Clin Exp Immunol (1999) 1.00
C-C chemokine-encoding DNA vaccines enhance breakdown of tolerance to their gene products and treat ongoing adjuvant arthritis. J Clin Invest (2000) 1.00
Murine oncostatin M stimulates mouse synovial fibroblasts in vitro and induces inflammation and destruction in mouse joints in vivo. Am J Pathol (2000) 0.99
The evolving systemic and local biomarker milieu at different stages of disease progression in rat adjuvant-induced arthritis. J Clin Immunol (2008) 0.99
Advanced imaging in rheumatoid arthritis. Part 1: synovitis. Skeletal Radiol (2006) 0.98
Immunomodulatory properties of human serum immunoglobulin A: anti-inflammatory and pro-inflammatory activities in human monocytes and peripheral blood mononuclear cells. Clin Exp Immunol (2005) 0.97
The potential of signal transduction inhibitors for the treatment of arthritis: Is it all just JNK? J Clin Invest (2001) 0.97
The oxazolidinone derivative locostatin induces cytokine appeasement. J Immunol (2009) 0.97
Anti-inflammatory effects of leflunomide on cultured synovial macrophages from patients with rheumatoid arthritis. Ann Rheum Dis (2003) 0.97
Physiologic role of interleukin-1 receptor antagonist. Arthritis Res (2000) 0.97
Disease-inducible transgene expression from a recombinant adeno-associated virus vector in a rat arthritis model. J Virol (1999) 0.96
Signal transduction by tumour necrosis factor and tumour necrosis factor related ligands and their receptors. Ann Rheum Dis (1999) 0.96
Collagen induced arthritis increases secondary metastasis in MMTV-PyV MT mouse model of mammary cancer. BMC Cancer (2011) 0.95
TNF receptor gene therapy results in suppression of IgG2a anticollagen antibody in collagen induced arthritis. Ann Rheum Dis (2003) 0.95
Destructive arthritis in vaccinated interferon gamma-deficient mice challenged with Borrelia burgdorferi: modulation by tumor necrosis factor alpha. Clin Diagn Lab Immunol (2003) 0.95
Autoantibodies against interleukin 1alpha in rheumatoid arthritis: association with long term radiographic outcome. Ann Rheum Dis (2002) 0.94
FK506 potently inhibits T cell activation induced TNF-alpha and IL-1beta production in vitro by human peripheral blood mononuclear cells. Br J Pharmacol (2000) 0.94
FcgammaRI up-regulation induced by local adenoviral-mediated interferon-gamma production aggravates chondrocyte death during immune complex-mediated arthritis. Am J Pathol (2003) 0.93
Effect of sildenafil citrate on interleukin-1beta-induced nitric oxide synthesis and iNOS expression in SW982 cells. Exp Mol Med (2008) 0.93
Active leflunomide metabolite inhibits interleukin 1beta, tumour necrosis factor alpha, nitric oxide, and metalloproteinase-3 production in activated human synovial tissue cultures. Ann Rheum Dis (2003) 0.92
THR0921, a novel peroxisome proliferator-activated receptor gamma agonist, reduces the severity of collagen-induced arthritis. Arthritis Res Ther (2006) 0.92
Suppression of complete Freund's adjuvant-induced adjuvant arthritis by cobratoxin. Acta Pharmacol Sin (2009) 0.91
Therapeutic efficacy of intra-articular adrenomedullin injection in antigen-induced arthritis in rabbits. Arthritis Res Ther (2008) 0.89
Flaxseed-a potential functional food source. J Food Sci Technol (2014) 0.89
Treatment of rheumatoid arthritis with interleukin 1 receptor antagonist. Ann Rheum Dis (1999) 0.89
Friends or Foes: Matrix Metalloproteinases and Their Multifaceted Roles in Neurodegenerative Diseases. Mediators Inflamm (2015) 0.89
Interleukin-1beta-mediated inhibition of the processes of angiogenesis in cardiac microvascular endothelial cells. Life Sci (2008) 0.88
Butrin, isobutrin, and butein from medicinal plant Butea monosperma selectively inhibit nuclear factor-kappaB in activated human mast cells: suppression of tumor necrosis factor-alpha, interleukin (IL)-6, and IL-8. J Pharmacol Exp Ther (2010) 0.88
Effects of induced mast cell activation on prostaglandin E and metalloproteinase production by rheumatoid synovial tissue in vitro. Ann Rheum Dis (1998) 0.88
Modulation of proinflammatory cytokine production in tumour necrosis factor-alpha (TNF-alpha)-transgenic mice by treatment with cells engineered to secrete IL-4, IL-10 or IL-13. Clin Exp Immunol (1998) 0.88
Histone deacetylase inhibitors: a new mode for inhibition of cholesterol metabolism. BMC Genomics (2008) 0.87
Human, viral or mutant human IL-10 expressed after local adenovirus-mediated gene transfer are equally effective in ameliorating disease pathology in a rabbit knee model of antigen-induced arthritis. Arthritis Res Ther (2006) 0.86
Etanercept treatment reduces the serum levels of interleukin-15 and interferon-gamma inducible protein-10 in patients with rheumatoid arthritis. Rheumatol Int (2010) 0.85
Regulation of inflammatory response in human chondrocytes by lentiviral mediated RNA interference against S100A10. Inflamm Res (2012) 0.85
Enforced expression of roquin protein in T cells exacerbates the incidence and severity of experimental arthritis. J Biol Chem (2012) 0.85
Gene therapy for autoimmune disorders. J Clin Immunol (2000) 0.85
Functional changes in rheumatoid fibroblast-like synovial cells through activation of peroxisome proliferator-activated receptor gamma-mediated signalling pathway. Clin Exp Immunol (2002) 0.85
Regulatory role of interleukin-10 in experimental group B streptococcal arthritis. Infect Immun (2002) 0.85
Tenidap decreases IL-8 and monocyte chemotactic peptide-1 (MCP-1) mRNA expression in the synovial tissue of rabbits with antigen arthritis and in cultured synovial cells. Clin Exp Immunol (1998) 0.84
Butyrate inhibits interleukin-1-mediated nuclear factor-kappa B activation in human epithelial cells. Dig Dis Sci (2001) 0.84
Type 1 regulatory T cells specific for collagen type II as an efficient cell-based therapy in arthritis. Arthritis Res Ther (2014) 0.84
Cartilage and bone macromolecules in knee joint synovial fluid in rheumatoid arthritis: relation to development of knee or hip joint destruction. Ann Rheum Dis (1997) 0.84
Lupeol, a triterpenoid isolated from Calotropis gigantea latex ameliorates the primary and secondary complications of FCA induced adjuvant disease in experimental rats. Inflammopharmacology (2011) 0.83
Building towards a consensus for the use of tumour necrosis factor blocking agents. Ann Rheum Dis (1999) 0.83
Tumour necrosis factor receptor gene therapy affects cellular immune responses in collagen induced arthritis in mice. Ann Rheum Dis (2005) 0.83
Glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans, inhibits the progression of group B streptococcal arthritis. Infect Immun (2004) 0.82
Gene therapy in rheumatoid arthritis: how to target joint destruction? Arthritis Res (1999) 0.82
Implication of interleukin 18 in production of matrix metalloproteinases in articular chondrocytes in arthritis: direct effect on chondrocytes may not be pivotal. Ann Rheum Dis (2005) 0.82
Link peptide cartilage growth factor is degraded by membrane proteinases. Biochem J (2000) 0.82
Effect and mechanism of AR-6 in experimental rheumatoid arthritis. Clin Exp Med (2009) 0.82
Abeta-immunotherapy for Alzheimer's disease using mannan-amyloid-Beta peptide immunoconjugates. DNA Cell Biol (2006) 0.82
Cytokines and cellular interactions in inflammatory synovitis. J Clin Invest (2001) 0.82
The Role of Chemokines in Shaping the Balance Between CD4(+) T Cell Subsets and Its Therapeutic Implications in Autoimmune and Cancer Diseases. Front Immunol (2015) 0.81
Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med (1985) 8.16
Effect of mechanical ventilation on inflammatory mediators in patients with acute respiratory distress syndrome: a randomized controlled trial. JAMA (1999) 7.37
Production of collagenase and prostaglandins by isolated adherent rheumatoid synovial cells. Proc Natl Acad Sci U S A (1976) 5.40
Stimulation of rheumatoid synovial cell collagenase and prostaglandin production by partially purified lymphocyte-activating factor (interleukin 1). Proc Natl Acad Sci U S A (1981) 4.89
Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. N Engl J Med (1988) 4.69
Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum (1990) 4.39
CCR5 is characteristic of Th1 lymphocytes. Nature (1998) 3.92
Human recombinant interleukin 1 stimulates collagenase and prostaglandin E2 production by human synovial cells. J Clin Invest (1986) 3.43
Participation of monocyte-macrophages and lymphocytes in the production of a factor that stimulates collagenase and prostaglandin release by rheumatoid synovial cells. J Clin Invest (1979) 3.34
Collagenase production by rheumatoid synovial cells: stimulation by a human lymphocyte factor. Science (1977) 2.91
Concomitant secretion of prourokinase and of a plasminogen activator-specific inhibitor by cultured human monocytes-macrophages. J Exp Med (1984) 2.78
Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann Rheum Dis (2000) 2.59
Prostaglandin production by rheumatoid synovial cells: stimulation by a factor from human mononuclear Cells. J Exp Med (1977) 2.47
Purification of a factor from human blood monocyte-macrophages which stimulates the production of collagenase and prostaglandin E2 by cells cultured from rheumatoid synovial tissues. FEBS Lett (1981) 2.27
A urine inhibitor of interleukin 1 activity that blocks ligand binding. J Immunol (1987) 2.17
Contribution of interleukin 17 to synovium matrix destruction in rheumatoid arthritis. Cytokine (2000) 2.11
Purification and biologic characterization of a specific tumor necrosis factor alpha inhibitor. J Biol Chem (1989) 2.07
High bronchoalveolar levels of tumor necrosis factor and its inhibitors, interleukin-1, interferon, and elastase, in patients with adult respiratory distress syndrome after trauma, shock, or sepsis. Am Rev Respir Dis (1992) 2.05
Relation between tumor necrosis factor-alpha and granulocyte elastase-alpha 1-proteinase inhibitor complexes in the plasma of patients with cystic fibrosis. Am Rev Respir Dis (1989) 1.99
Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol (1998) 1.97
Purification and characterization of human interleukin-1 beta expressed in recombinant Escherichia coli. Eur J Biochem (1986) 1.89
A human inhibitor of tumor necrosis factor alpha. J Exp Med (1988) 1.85
Increased prostaglandin production by human monocytes after membrane receptor activation. J Immunol (1979) 1.77
Synthesis of interleukin 1/endogenous pyrogen in the brain of endotoxin-treated mice: a step in fever induction? J Immunol (1984) 1.71
Prostaglandin E2 and collagenase production by fibroblasts and synovial cells is regulated by urine-derived human interleukin 1 and inhibitor(s). J Clin Invest (1986) 1.70
Interleukin 1 is present in normal human epidermis. J Immunol (1986) 1.70
Allergen immunotherapy: therapeutic vaccines for allergic diseases. World Health Organization. American academy of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol (1998) 1.70
IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes. J Clin Invest (1995) 1.69
Induction of human interleukin 1 mRNA measured by collagenase- and prostaglandin E2-stimulating activity in rheumatoid synovial cells. Eur J Immunol (1984) 1.66
Purified blood monocytes from HIV 1-infected patients produce high levels of TNF alpha and IL-1. Clin Immunol Immunopathol (1989) 1.63
IFN-gamma and 1,25(OH)2D3 induce on THP-1 cells distinct patterns of cell surface antigen expression, cytokine production, and responsiveness to contact with activated T cells. J Immunol (1992) 1.62
Crucial role of tumor necrosis factor (TNF) receptor 2 and membrane-bound TNF in experimental cerebral malaria. Eur J Immunol (1997) 1.56
Natural and recombinant human IL-1 receptor antagonists block the effects of IL-1 on bone resorption and prostaglandin production. J Immunol (1990) 1.48
Macrophage inflammatory protein-1: a prostaglandin-independent endogenous pyrogen. Science (1989) 1.46
Cytokines and other mediators in rheumatoid arthritis. Springer Semin Immunopathol (1984) 1.45
A urine inhibitor of interleukin 1 activity affects both interleukin 1 alpha and 1 beta but not tumor necrosis factor alpha. J Immunol (1987) 1.44
Suppression of metalloproteinase biosynthesis in human alveolar macrophages by interleukin-4. J Clin Invest (1992) 1.38
Direct contact between T lymphocytes and monocytes is a major pathway for induction of metalloproteinase expression. J Biol Chem (1994) 1.36
Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity. J Rheumatol (1997) 1.32
Characterization of a tumor necrosis factor alpha (TNF-alpha) inhibitor: evidence of immunological cross-reactivity with the TNF receptor. Proc Natl Acad Sci U S A (1990) 1.30
Imbalance between interstitial collagenase and tissue inhibitor of metalloproteinases 1 in synoviocytes and fibroblasts upon direct contact with stimulated T lymphocytes: involvement of membrane-associated cytokines. Arthritis Rheum (1998) 1.30
Limited effects of recombinant human and murine interleukin 1 and tumour necrosis factor on production of acute phase proteins by cultured rat hepatocytes. Biochem Int (1987) 1.30
The effects of interferon-beta treatment of synovial inflammation and expression of metalloproteinases in patients with rheumatoid arthritis. Arthritis Rheum (2000) 1.29
Matrix metalloproteinases and TIMP in acute respiratory distress syndrome. Am J Respir Crit Care Med (1996) 1.29
Purification and characterization of human interleukin-1 alpha produced in Escherichia coli. Eur J Biochem (1987) 1.28
Cell surface glycoproteins expressed on activated human T cells induce production of interleukin-1 beta by monocytic cells: a possible role of CD69. Eur Cytokine Netw (1993) 1.26
Killing of Staphylococcus aureus by tumor necrosis factor-alpha-activated neutrophils. The role of serum opsonins, integrin receptors, respiratory burst, and degranulation. J Immunol (1993) 1.25
Interactions among rheumatoid synovial cells and monocyte-macrophages: production of collagenase-stimulating factor by human monocytes exposed to concanavalin A or immunoglobulin Fc fragments. J Immunol (1980) 1.24
The functional importance of a cap site-proximal region of the human prointerleukin 1 beta gene is defined by viral protein trans-activation. Mol Cell Biol (1992) 1.24
Interferon-beta not only inhibits interleukin-1beta and tumor necrosis factor-alpha but stimulates interleukin-1 receptor antagonist production in human peripheral blood mononuclear cells. Eur Cytokine Netw (1997) 1.23
Mononuclear cell-conditioned medium containing mononuclear cell factor (MCF), homologous with interleukin 1, stimulates collagen and fibronectin synthesis by adherent rheumatoid synovial cells: effects of prostaglandin E2 and indomethacin. Coll Relat Res (1985) 1.22
Localization of [3H]ouabain-sensitive Na+ pump sites in cultured pig kidney cells. Am J Physiol (1979) 1.19
Specific interleukin-1 inhibitor in serum and urine of children with systemic juvenile chronic arthritis. Lancet (1987) 1.19
Human Th1 cells preferentially induce interleukin (IL)-1beta while Th2 cells induce IL-1 receptor antagonist production upon cell/cell contact with monocytes. Eur J Immunol (1997) 1.18
Procalcitonin, IL-6, IL-8, IL-1 receptor antagonist and C-reactive protein as identificators of serious bacterial infections in children with fever without localising signs. Eur J Pediatr (2001) 1.18
Modulation of endotoxic activity of lipopolysaccharide by high-density lipoprotein. Pathobiology (1991) 1.17
Imbalance between tumour necrosis factor-alpha and soluble TNF receptor concentrations in severe meningococcaemia. The J5 Study Group. Immunology (1992) 1.16
The insulin receptor of a human monocyte-like cell line: characterization and function. Endocrinology (1984) 1.16
Production of monoclonal antibodies against interleukin-1 alpha and -1 beta. Development of two enzyme immunometric assays (EIA) using acetylcholinesterase and their application to biological media. J Immunol Methods (1989) 1.15
The inhibitory activity of human interleukin-1 receptor antagonist is enhanced by type II interleukin-1 soluble receptor and hindered by type I interleukin-1 soluble receptor. J Clin Invest (1995) 1.15
Rheumatoid synovial cell morphologic changes induced by a mononuclear cell factor in culture. Arthritis Rheum (1983) 1.14
Induction of plasma inhibitors of interleukin 1 and TNF-alpha activity by endotoxin administration to normal humans. Am J Physiol (1990) 1.14
A cell strain cultured from porcine kidney increases cyclic AMP content upon exposure to calcitonin or vasopressin. Biochem Biophys Res Commun (1978) 1.14
Cytokines, metalloproteinases, their inhibitors and cartilage oligomeric matrix protein: relationship to radiological progression and inflammation in early rheumatoid arthritis. A prospective 5-year study. Rheumatology (Oxford) (2001) 1.14
Concentrations and origins of soluble interleukin 6 receptor-alpha in serum and synovial fluid. J Rheumatol (1997) 1.13
Inhibition by retinoic acid of collagenase production in rheumatoid synovial cells. N Engl J Med (1980) 1.12
Successful treatment of polyarteritis nodosa related to hepatitis B virus with a combination of lamivudine and interferon alpha. Rheumatology (Oxford) (1999) 1.12
Elevated serum levels of interleukin-1 receptor antagonist in polymyositis/dermatomyositis. A biologic marker of disease activity with a possible role in the lack of acute-phase protein response. Arthritis Rheum (1994) 1.12
Purification and characterization of a 26-kDa competitive inhibitor of interleukin 1. Eur J Immunol (1990) 1.10
Macrophage activation syndrome and rheumatic disease in childhood: a report of four new cases. Clin Exp Rheumatol (1993) 1.09
IFN-beta inhibits the ability of T lymphocytes to induce TNF-alpha and IL-1beta production in monocytes upon direct cell-cell contact. Cytokine (2001) 1.09
Normal epidermis contains high amounts of natural tissue IL 1 biochemical analysis by HPLC identifies a MW approximately 17 Kd form with a P1 5.7 and a MW approximately 30 Kd form. Lymphokine Res (1986) 1.09
Soluble tumor necrosis factor receptors in human inflammatory synovial fluids. Arthritis Rheum (1993) 1.08
Tumor necrosis factor and interleukin-1 activities in free lung cells after single and repeated inhalation of bacterial endotoxin. Infect Immun (1991) 1.07
Characterization of cells from human giant cell tumors of bone. Clin Orthop Relat Res (1986) 1.07
Contact-dependent stimulation of monocytic cells and neutrophils by stimulated human T-cell clones. Immunology (1995) 1.07
Serum cytokine changes in systemic vasculitis. Immunology (1989) 1.05
The role of cytokines and their inhibitors in arthritis. Baillieres Clin Rheumatol (1992) 1.04
Exposure of T lymphocytes to leflunomide but not to dexamethasone favors the production by monocytic cells of interleukin-1 receptor antagonist and the tissue-inhibitor of metalloproteinases-1 over that of interleukin-1beta and metalloproteinases. Eur Cytokine Netw (1998) 1.02
Some recombinant human cytokines stimulate glycosaminoglycan synthesis in human synovial fibroblast cultures and inhibit it in human articular cartilage cultures. Arthritis Rheum (1989) 1.01
Expression and cleavage of tumor necrosis factor-alpha and tumor necrosis factor receptors by human monocytic cell lines upon direct contact with stimulated T cells. Eur J Immunol (1996) 1.01
Production of interleukin-1 (IL-1) and a specific IL-1 inhibitor during human monocyte-macrophage differentiation: influence of GM-CSF. Cytokine (1989) 1.01
Dynamics of fever and the cytokine network in systemic juvenile arthritis. Rev Rhum Engl Ed (1996) 1.01
Killing of Plasmodium falciparum by cytokine activated effector cells (neutrophils and macrophages). Immunol Lett (1990) 1.01
Dysregulation of the in vivo production of interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Pathogenetic implications. Arthritis Rheum (1995) 1.00
Regulation by Fc fragments of the secretion of collagenase, PGE2, and lysozyme by mouse peritoneal macrophages. J Immunol (1980) 1.00
Interferon gamma drastically modifies the regulation of interleukin 1 genes by endotoxin in U937 cells. J Clin Invest (1990) 1.00
Increased expression of tissue inhibitor of metalloproteinase-1 and loss of correlation with matrix metalloproteinase-9 by macrophages in asthma. Lab Invest (1999) 1.00
Calcitonin stimulates plasminogen activator in porcine renal tubular cells: LLC-PK1. J Cell Biol (1981) 0.98
Parathyroid hormone inhibitors: comparison of biological activity in bone- and skin-derived tissue. J Clin Endocrinol Metab (1979) 0.98
Effect of leukotriene B4, prostaglandin E2 and arachidonic acid on cytosolic-free calcium in human neutrophils. FEBS Lett (1984) 0.97
Interleukin (IL)-6 and its soluble receptor induce TIMP-1 expression in synoviocytes and chondrocytes, and block IL-1-induced collagenolytic activity. J Biol Chem (1998) 0.97
Self-associating IgG rheumatoid factors stimulate monocytes to release prostaglandins and mononuclear cell factor that stimulates collagenase and prostaglandin production by synovial cells. Rheumatol Int (1983) 0.97
Tumour necrosis factor soluble receptors behave as acute phase reactants following surgery in patients with rheumatoid arthritis, chronic osteomyelitis and osteoarthritis. Clin Exp Immunol (1993) 0.97
Phase I/II trial of recombinant methionyl human tumor necrosis factor binding protein PEGylated dimer in patients with active refractory rheumatoid arthritis. J Rheumatol (2000) 0.96
Pulmonary fibrosis with predominant CD8 lymphocytic alveolitis and anti-Jo-1 antibodies. Eur Respir J (1997) 0.96